Bristol-Myers AASLD hepatitis C data focus on hard-to-treat
This article was originally published in Scrip
Hepatitis C is a difficult market to enter when new drugs with high cure rates are instant blockbusters, but the strategy at Bristol-Myers Squibb is to focus on difficult populations, such as patients with genotype 3 hepatitis C virus (HCV) or genotype 1 HCV patients with cirrhosis or HIV, and potentially shorten the duration of treatment.
You may also be interested in...
Private Company Edition: TVM, Focus/MD Anderson and RA Capital launched new venture capital funds. Also, LianBio’s $310m crossover financing, AavantiBio’s Sarepta-backed $107m series A and Sirnaomics’ $105m series D led recent VC rounds.
Amgen had a good third quarter despite some COVID-19 impacts but did not shed any light on filing plans for two key late-stage programs nor provide any insight into Phase III asthma results for tezepelumab.
Merck’s third quarter beat analyst consensus and the company raised its guidance. The COVID-19-battered vaccines business began to improve but Gardasil’s recovery was slower than expected.